SCHEMBL6458566

SCHEMBL6458566

Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@H]1CC[C@@H](Nc2cc(N(C)C)c3ccccc3n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.52
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 3/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 3/20 0.46
ATM Q13315 2/20 0.46
GLA P06280 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 2/20 0.46
PPARG P37231 1/20 0.45
NCOA2 Q15596 1/20 0.45
TSHR P16473 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6463675 1.00 GHSR (0.52) GHSRALDH1A1KDM4ENPSR1POLB
SCHEMBL6457757 0.95 GHSR (0.57) GHSRALDH1A1KDM4ENPSR1KMT2A
SCHEMBL6457762 0.95 GHSR (0.57) GHSRALDH1A1KDM4ENPSR1KMT2A
SCHEMBL6460655 0.90 KMT2A (0.61) GHSRALDH1A1KDM4ENPSR1KMT2A
SCHEMBL6460650 0.90 KMT2A (0.61) GHSRALDH1A1KDM4ENPSR1KMT2A
SCHEMBL13793328 0.85 MCHR1 (0.64) GHSRALDH1A1KDM4ENPSR1POLB
SCHEMBL4262243 0.84 GHSR (0.55) GHSRALDH1A1POLBKMT2AMEN1
SCHEMBL4262247 0.84 GHSR (0.55) GHSRALDH1A1POLBKMT2AMEN1
SCHEMBL6874162 0.81 MCHR1 (0.54) KDM4ESMN1; SMN2LMNA
SCHEMBL6874154 0.81 MCHR1 (0.54) KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 GHSR 388/4885ALDH1A1 2036/4885KDM4E 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.